Date of Award
Selective Evidence-Based Medicine Review
Master of Science in Health Sciences - Physician Assistant
Physician Assistant Studies
OBJECTIVE: The objective of this selective EBM review is to assess if risankizumab is effective in decreasing the percentage of scaling and body surface area affected amongst those with moderate to severe plaque psoriasis.
STUDY DESIGN: A review of three peer-reviewed randomized controlled trials published between 2015-2018.
DATA SOURCES: The three randomized controlled trials were located using the PubMed database. The studies were selected based upon patient-oriented evidence that matters (POEMs) in correlation to answering the question proposed.
OUTCOMES MEASURED: Outcomes were measured through the Psoriasis Area Severity Index Score.
RESULTS: The studies done by Gordon et al., Krueger et al., and Papp et al., all found statistically significant results (p values < 0.0001, 0.05, and 0.001) when assessing the efficacy of risankizumab vs comparison groups in decreasing the percentage of scaling and body surface area affected in patients with moderate to severe plaque psoriasis.
CONCLUSIONS: The evidence presented within the three randomized control trials demonstrate a statistically significant relationship between risankizumab and its proficiency in treating the symptoms associated with moderate to severe plaque psoriasis.
Berry, Angel L., "Is Risankizumab Effective in Decreasing Scaling and Percentage of Body Surface Area Affected Amongst Adults with Moderate-Severe Plaque Psoriasis?" (2021). PCOM Physician Assistant Studies Student Scholarship. 613.